Predicting manufacturing capacity needs for a pipeline of Cell & Gene Therapy products is an exercise with high stakes and enormous uncertainty. A large biotechnology company came to Dark Horse for assistance in identifying the manufacturing facility needs of its cell therapy product pipeline in the face of a wide range of development and commercial assumptions.
The client received a highly-customized, probability-weighted picture of the likely range of capacity needs and manufacturing costs for its cell therapy product pipeline, based on Monte Carlo modeling of a range of input assumptions. This hard data provided them with the ability to make rational choices in their facility design process, as well as to increase the accuracy of their financial forecasts.
The modeling software Dark Horse uses is a proprietary, in-house offering, built specifically from the ground up to factor in the many complexities and variables inherent to the C> industry.
As with any model, the output will only be as good as the inputs. DHC’s platform has been designed to capture the breadth of input assumptions, such as materials costs, process duration and yield, clinical enrollment, probabilities of success, and timeframes for each phase of development. Our platform then simulates the range of potential outcomes with distributions and Monte Carlo algorithms. Identifying the range for these parameters can be daunting, but our team is equipped to provide help based on process specifics and industry standards. Our platform provides the full range and probabilities of outcomes, making it easier to develop strategies based on risk and control.